Skip to main content

Advertisement

SpringerLink
Log in

Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

An Erratum to this article was published on 27 February 2017

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Change history

  • 27 February 2017

    An erratum to this article has been published.

References

  1. V. Marotta, C. Sciammarella, M. Vitale, A. Colao, A. Faggiano, The evolving field of kinase inhibitors in thyroid cancer. Crit. Rev. Oncol. Hematol. 93(1), 60–73 (2015). doi:10.1016/j.critrevonc.2014.08.007

    Article  CAS  Google Scholar 

  2. S. Bulotta, M. Celano, G. Costante, D. Russo, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52(2), 214–221 (2016). doi:10.1007/s12020-015-0830-4

    Article  CAS  PubMed  Google Scholar 

  3. M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Pena, I. Molnar, M.J. Schlumberger: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. (2014). doi:10.1016/S0140-6736(14)60421-9.

  4. M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015). doi:10.1056/NEJMoa1406470

    Article  PubMed  Google Scholar 

  5. V. Marotta, V. Ramundo, L. Camera, M. Del Prete, R. Fonti, R. Esposito, G. Palmieri, M. Salvatore, M. Vitale, A. Colao, A. Faggiano, Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin. Endocrinol. (Oxf). 78(5), 760–767 (2013). doi:10.1111/cen.12057

    Article  CAS  PubMed  Google Scholar 

  6. M. Gallo, F. Michelon, A. Castiglione, F. Felicetti, A.A. Viansone, A. Nervo, C. Zichi, G. Ciccone, A. Piovesan, E. Arvat, Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine 49(3), 726–734 (2015). doi:10.1007/s12020-014-0481-x

    Article  CAS  PubMed  Google Scholar 

  7. M. Caraglia, P. Tassone, M. Marra, A. Budillon, S. Venuta, P. Tagliaferri, Targeting Raf-kinase: molecular rationales and translational issues. Ann. Oncol. 17 Suppl 7, vii124–127 (2006). doi:10.1093/annonc/mdl964

    CAS  PubMed  Google Scholar 

  8. M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13(3), 184–199 (2013). doi:10.1038/nrc3431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, P.A. Trail, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004). doi:10.1158/0008-5472.CAN-04-1443

    Article  CAS  PubMed  Google Scholar 

  10. I. Pantsulaia, S. Trofimov, E. Kobyliansky, G. Livshits, Heritability of circulating growth factors involved in the angiogenesis in healthy human population. Cytokine 27(6), 152–158 (2004). doi:10.1016/j.cyto.2004.04.005

    Article  CAS  PubMed  Google Scholar 

  11. J.A. Nagy, A.M. Dvorak, H.F. Dvorak, VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251–275 (2007). doi:10.1146/annurev.pathol.2.010506.134925

    Article  CAS  PubMed  Google Scholar 

  12. M. Shahbazi, A.A. Fryer, V. Pravica, I.J. Brogan, H.M. Ramsay, I.V. Hutchinson, P.N. Harden, Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 13(1), 260–264 (2002)

    CAS  Google Scholar 

  13. Y. Wang, Y. Zheng, W. Zhang, H. Yu, K. Lou, Y. Zhang, Q. Qin, B. Zhao, Y. Yang, R. Hui, Polymorphisms of KDR gene are associated with coronary heart disease. J. Am. Coll. Cardiol. 50(8), 760–767 (2007). doi:10.1016/j.jacc.2007.04.074

    Article  CAS  PubMed  Google Scholar 

  14. M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356–358 (2014). doi:10.1016/S2213-8587(13)70215-8

    Article  Google Scholar 

  15. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009). doi:10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  16. T.F. Hansen, K.L. Spindler, K.A. Lorentzen, D.A. Olsen, R.F. Andersen, J. Lindebjerg, I. Brandslund, A. Jakobsen, The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J. Cancer Res. Clin. Oncol. 136(5), 751–758 (2010). doi:10.1007/s00432-009-0714-1

    Article  CAS  PubMed  Google Scholar 

  17. C.J. Watson, N.J. Webb, M.J. Bottomley, P.E. Brenchley, Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8), 1232–1235 (2000). doi:10.1006/cyto.2000.0692

    Article  CAS  PubMed  Google Scholar 

  18. W. Renner, S. Kotschan, C. Hoffmann, B. Obermayer-Pietsch, E. Pilger, A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37(6), 443–448 (2000).

    Article  CAS  PubMed  Google Scholar 

  19. K. Dassoulas, M. Gazouli, S. Rizos, G. Theodoropoulos, Z. Christoni, N. Nikiteas, P. Karakitsos, Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 48(6), 563–569 (2009). doi:10.1002/mc.20495

    Article  CAS  PubMed  Google Scholar 

  20. Y. Kawai, S. Sakano, Y. Korenaga, S. Eguchi, K. Naito, Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur. Urol. 52(4), 1147–1155 (2007). doi: 10.1016/j.eururo.2007.01.073

    Article  CAS  PubMed  Google Scholar 

  21. E.L. Goode, M.J. Maurer, T.A. Sellers, C.M. Phelan, K.R. Kalli, B.L. Fridley, R.A. Vierkant, S.M. Armasu, K.L. White, G.L. Keeney, W.A. Cliby, D.N. Rider, L.E. Kelemen, M.B. Jones, P.P. Peethambaram, J.M. Lancaster, J.E. Olson, J.M. Schildkraut, J.M. Cunningham, L.C. Hartmann, Inherited determinants of ovarian cancer survival. Clin. Cancer Res. 16(3), 995–1007 (2010). doi:10.1158/1078-0432.CCR-09-2553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. F. Lose, C.M. Nagle, T. O’Mara, J. Batra, K.L. Bolton, H. Song, S.J. Ramus, A. Gentry-Maharaj, U. Menon, S.A. Gayther, P.D. Pharoah, M.A. Kedda, A.B. Spurdle, Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol. Oncol. 119(3), 479–483 (2010). doi:10.1016/j.ygyno.2010.08.014

    Article  CAS  PubMed  Google Scholar 

  23. R.S. Heist, R. Zhai, G. Liu, W. Zhou, X. Lin, L. Su, K. Asomaning, T.J. Lynch, J.C. Wain, D.C. Christiani, VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 26(6), 856–862 (2008). doi:10.1200/JCO.2007.13.5947

    Article  CAS  PubMed  Google Scholar 

  24. D. Sa-Nguanraksa, T. Chuangsuwanich, T. Pongpruttipan, T. Kummalue, S. Rojananin, A. Ratanawichhitrasin, P. Prasarttong-Osoth, S. Chuthatisith, P. Pisarnturakit, W. Aeumrithaicharoenchok, P. Rushatamukayanunt, V. Lohsiriwat, M. Boonsripitayanon, P. Malasit, P. O-Charoenrat, Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol. Med. Rep. 8(4), 1242–1250 (2013). doi:10.3892/mmr.2013.1607

    CAS  PubMed  Google Scholar 

  25. G. Lurje, W. Zhang, A.M. Schultheis, D. Yang, S. Groshen, A.E. Hendifar, H. Husain, M.A. Gordon, F. Nagashima, H.M. Chang, H.J. Lenz, Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann. Oncol. 19(10), 1734–1741 (2008). doi:10.1093/annonc/mdn368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. T.F. Hansen, F.B. Sorensen, K.L. Spindler, D.A. Olsen, R.F. Andersen, J. Lindebjerg, I. Brandslund, A. Jakobsen, Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows. Arch. 456(3), 251–260 (2010). doi:10.1007/s00428-009-0878-8

    Article  CAS  PubMed  Google Scholar 

  27. M.K. Kim, C. Suh, H.S. Chi, H.S. Cho, Y.K. Bae, K.H. Lee, G.W. Lee, I.S. Kim, H.S. Eom, S.Y. Kong, S.H. Bae, H.M. Ryoo, I.H. Shin, Y.C. Mun, H. Chung, M.S. Hyun, VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci. 103(3), 497–503 (2012). doi:10.1111/j.1349-7006.2011.02168.x

    Article  CAS  PubMed  Google Scholar 

  28. A.B. Kilicarslan, M. Ogus, C. Arici, H.E. Pestereli, M. Cakir, G. Karpuzoglu, Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 111(3), 439–443 (2003).

    Article  CAS  PubMed  Google Scholar 

  29. J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, H. Kardymowicz, The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter. Eur. J. Endocrinol. 157(4), 521–527 (2007). doi:10.1530/EJE-07-0252

    Article  CAS  PubMed  Google Scholar 

  30. M.B. Bass, S.I. Sherman, M.J. Schlumberger, M.T. Davis, L. Kivman, H.M. Khoo, K.H. Notari, M. Peach, Y.J. Hei, S.D. Patterson, Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 95(11), 5018–5027 (2010). doi:10.1210/jc.2010-0947

    Article  CAS  PubMed  Google Scholar 

  31. V. Marotta, C. Sciammarella, M. Capasso, A. Testori, C. Gambardella, M. Grasso, M. Rubino, M. De Palma, M.G. Chiofalo, C. Pivonello, R. Pivonello, L. Santini, L. Pezzullo, A. Colao, A. Faggiano, Analysis of germline VEGF-A SNPs allows the identification of a subgroup of ATA low-intermediate risk DTC (differentiated thyroid cancer) patients with poor probability to develop recurrences. Endocr. Abstr. 41, GP230 (2016). doi:10.1530/endoabs.41.GP230

    Google Scholar 

  32. V.M. Leppanen, A.E. Prota, M. Jeltsch, A. Anisimov, N. Kalkkinen, T. Strandin, H. Lankinen, A. Goldman, K. Ballmer-Hofer, K. Alitalo, Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. USA 107(6), 2425–2430 (2010). doi:10.1073/pnas.0914318107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. A.T. Hattersley, M.I. McCarthy, What makes a good genetic association study? Lancet. 366(9493), 1315–1323 (2005). doi:10.1016/S0140-6736(05)67531-9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IOS & COLEMAN Srl, Naples, Italy

    Vincenzo Marotta & Concetta Sciammarella

  2. CEINGE Biotecnologie Avanzate, Federico II University, Naples, Italy

    Mario Capasso & Alessandro Testori

  3. Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

    Claudia Pivonello, Rosario Pivonello & Annamaria Colao

  4. Thyroid and Parathyroid Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori-IRCCS “Fondazione G. Pascale”, Naples, Italy

    Maria Grazia Chiofalo, Luciano Pezzullo & Antongiulio Faggiano

  5. Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori-IRCCS “Fondazione G. Pascale”, Naples, Italy

    Gerardo Botti

Authors
  1. Vincenzo Marotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Concetta Sciammarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Capasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Testori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Grazia Chiofalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rosario Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luciano Pezzullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gerardo Botti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Annamaria Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Antongiulio Faggiano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Marotta.

Ethics declarations

Conflict of interest

All the authors declares that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

An erratum to this article is available at https://doi.org/10.1007/s12020-017-1269-6.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marotta, V., Sciammarella, C., Capasso, M. et al. Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine 57, 539–543 (2017). https://doi.org/10.1007/s12020-016-1200-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-1200-6

Keywords

Search

Navigation